Changes

no edit summary
Line 1,692: Line 1,692:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Diffuse large B-cell lymphoma, NOS||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
 
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
Line 1,699: Line 1,699:  
|
 
|
 
|-
 
|-
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,706: Line 1,706:  
|
 
|
 
|-
 
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
Line 1,713: Line 1,713:  
|
 
|
 
|-
 
|-
|ALK-positive large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
 
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
Line 1,720: Line 1,720:  
|
 
|
 
|-
 
|-
|Large B-cell lymphoma with IRF4 rearrangement||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|*Afia Hasnain, MBBS, PhD
 
|*Afia Hasnain, MBBS, PhD
Line 1,727: Line 1,727:  
|
 
|
 
|-
 
|-
|High grade B-cell lymphoma with 11q aberrations||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
 
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
Line 1,734: Line 1,734:  
|
 
|
 
|-
 
|-
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,741: Line 1,741:  
|
 
|
 
|-
 
|-
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,748: Line 1,748:  
|
 
|
 
|-
 
|-
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,755: Line 1,755:  
|
 
|
 
|-
 
|-
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,762: Line 1,762:  
|
 
|
 
|-
 
|-
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,769: Line 1,769:  
|
 
|
 
|-
 
|-
|Plasmablastic lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)